Growth Hormone-Induced Stridor in a Patient With Prader-Willi Syndrome.

Area of Science:

• Pediatric Endocrinology
• Otolaryngology
• Genetics

Background:

• Growth hormone (GH) therapy is crucial for managing conditions like Prader-Willi Syndrome (PWS).
• GH therapy is linked to potential upper airway issues, including obstruction and tissue hypertrophy.
• Airway complications can occur even without pre-existing adenotonsillar tissue.

Purpose of the Study:

• To highlight the risk of medication-induced airway changes during growth hormone therapy in PWS patients.
• To emphasize the importance of considering airway complications in PWS patients with complex airway histories.
• To guide clinicians in optimizing management strategies for these patients.

Main Methods:

• Review of clinical observations and literature regarding GH therapy and airway complications in PWS.
• Analysis of potential mechanisms for airway changes induced by GH.
• Case study considerations for patients with complex airway histories.

Main Results:

• Growth hormone therapy can lead to glottic or subglottic edema and stridor.
• These airway changes may manifest irrespective of adenotonsillar tissue presence.
• Complex airway histories in PWS patients necessitate careful consideration of GH-related risks.

Conclusions:

• Clinicians must be vigilant for GH-induced airway changes in PWS patients.
• Airway evaluation and monitoring are essential during GH therapy for PWS.
• Proactive management of medication-induced airway complications is critical for patient safety and treatment efficacy.